Observational studyMultiple sclerosis (Houndmills, Basingstoke, England)2020
Effect of disease-modifying therapies on subcortical gray matter atrophy in multiple sclerosis.
Observational study in Multiple sclerosis (Houndmills, Basingstoke, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 37 citations in OpenAlex.
- Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis.Journal of neurology, neurosurgery, and psychiatry · 2023Trial
- The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis.European radiology · 2022Trial
- Cognitive functioning in multiple sclerosis with focus on brainstem volume.Acta neurologica Belgica · 2026Article
- Decoding Thalamic Glial Interplay in Multiple Sclerosis Through Proton Magnetic Resonance Spectroscopy and Positron Emission Tomography.International journal of molecular sciences · 2025Article
- Decoding Gray Matter Involvement in Multiple Sclerosis via Imaging.Neuroimaging clinics of North America · 2024Review
- Myeloid cell-associated aromatic amino acid metabolism facilitates CNS myelin regeneration.NPJ Regenerative medicine · 2024Article
- Associations of sNfL with clinico-radiological measures in a large MS population.Annals of clinical and translational neurology · 2023Article
- Trans-Synaptic Degeneration Following Acute Optic Neuritis in Multiple Sclerosis.Annals of neurology · 2023Article
- Patterns of brain atrophy in recently-diagnosed relapsing-remitting multiple sclerosis.PloS one · 2023Article
- Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Article
- Tissue damage detected by quantitative gradient echo MRI correlates with clinical progression in non-relapsing progressive MS.Multiple sclerosis (Houndmills, Basingstoke, England) · 2022Article
- Visual imaging as a predictor of neurodegeneration in experimental autoimmune demyelination and multiple sclerosis.Acta neuropathologica communications · 2022Article
- Brain atrophy patterns in multiple sclerosis patients treated with natalizumab and its clinical correlates.Brain and behavior · 2022Article
- Early Aggressive Treatment Approaches for Multiple Sclerosis.Current treatment options in neurology · 2021Review
- Disease-modifying therapy aids cognition in multiple sclerosis.Nature reviews. Neurology · 2020Article
- Intrinsic and Extrinsic Mechanisms of Thalamic Pathology in Multiple Sclerosis.Annals of neurology · 2020Article
- Thalamic Atrophy Predicts 5-Year Disability Progression in Multiple Sclerosis.Frontiers in neurology · 2020Article
- Association between brain volume and disability over time in multiple sclerosis.Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThe effects of disease-modifying therapies (DMTs) on region-specific brain atrophy in multiple sclerosis (MS) are unclear.
objectiveTo determine the effects of higher versus lower efficacy DMTs on rates of brain substructure atrophy in MS.
methodsA non-randomized, observational cohort of people with MS followed with annual brain magnetic resonance imaging (MRI) was evaluated retrospectively. Whole brain, subcortical gray matter (GM), cortical GM, and cerebral white matter (WM) volume fractions were obtained. DMTs were categorized as higher (DMT-H: natalizumab and rituximab) or lower (DMT-L: interferon-beta and glatiramer acetate) efficacy. Follow-up epochs were analyzed if participants had been on a DMT for ⩾6 months prior to baseline and had at least one follow-up MRI while on DMTs in the same category.
resultsA total of 86 DMT epochs (DMT-H:
conclusionDMT-H treatment may be associated with slower rates of subcortical GM atrophy, especially of the thalamus and putamen. Thalamic and putaminal volumes are promising imaging biomarkers in MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.